Abstracts

Characterizing New and Boosted HIV-Specific T-Cell Responses Elicited by an HIV Therapeutic Vaccine

Background: Little is known about the capacity of HIV therapeutic vaccines to overcome pre-existing immunodominance hierarchies and elicit functional, long-lived new or boosted HIV-specific CD8+ T cell responses. We previously reported therapeutic vaccine-induced new and boosted HIV-specific T cell responses in people with HIV on ART in the PENNVAX trial. We now characterize the magnitude,…

Sex-Specific Transcriptional Profiles Associate With Severe SARS-CoV-2 Infection

Background: Rates of severe disease and death from SARS-CoV-2 infection are higher in males than in females, but the mechanisms are unclear. We interrogated the transcriptional profile associated with severe disease in males and females to investigate differences in pathogenesis. Methods: Individuals with SARS-CoV-2 in the CCPSEI cohort from 4-7/2020(Cohort 1) and 7/2020-1/2021(Cohort 2) were…

Peripheral Immune Progression to Long COVID (LC) Is Driven by Mitochondrial Gene Transcription

Background: Long COVID (LC) affects about 10% of persons infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) and can have serious clinical consequences. Whereas the pathophysiology of LC is likely multifactorial, several hypotheses have been proposed, including viral persistence in some individuals for months following the acute phase of COVID-19. Herein, we analyzed existing human…

Heterologous mRNA-1273 Boost After Ad26.CoV2.S Prime in Health Workers in South Africa: SHERPA Trial

Background: Given limited data on safety and effectiveness of heterologous Covid-19 vaccine boosting in lower income settings with high HIV prevalence, we evaluated an ancestral strain mRNA-1273 vaccine boost after priming with Ad26.COV2.S in South Africa. Methods: SHERPA was a single-arm, open-label, phase 3 study nested in the national Sisonke implementation trial of 500000 health…

Effectiveness and Safety of SARS-CoV-2 mRNA Vaccines in Children: A Population-Based Study in Madrid

Background: Decisions about COVID-19 vaccination in children require an assessment of benefits such as prevention of COVID-19 hospitalization and multisystem inflammatory syndrome in children (MIS-C), as well as of risks such as myocarditis. In the absence of large, randomized trials, this evidence needs to be obtained from prospective observational studies conducted in large populations over…

Spike-V987H Vaccination Protects Animal Models From SARS-COV-2–Induced Severe Disease

Background: Most SARS-CoV-2 vaccines are based on a two-prolines (K986P and V987P) stabilized Spike (S) glycoprotein (S-2P). Although these mutations improve S stability and immunogenicity, S-2P is produced at low levels yet. Here we explored new S protein stabilization approaches. Methods: We have investigated the immunogenicity and efficacy of a novel set of stabilizing mutations…

Distinct Absence of Post-Boost S-IgG Surge in Sub-Saharan African COVID-19 Vaccine Responses

Background: This study investigated the longitudinal antibody response profiles and their durability after administering various COVID-19 vaccines to a subset of the Ugandan population within Sub-Saharan Africa (SSA). The hypothesis was that these profiles in SSA may exhibit unique characteristics due to genetic, environmental, or serological variations, thereby addressing significant gaps in global datasets and…

Bivalent mRNA COVID Vaccines Elicit Predominantly Cross-Reactive CD4+ T-Cell Clonotypes

Background: The emergence of the Omicron BA.5 sublineage in February 2022 raised concerns due to its ability to escape neutralizing antibodies induced by ancestral spike mRNA vaccines and natural infection with prior SARS-CoV-2 variants. Bivalent COVID-19 vaccines, containing mRNA for both ancestral and Omicron BA.5 spike proteins, were developed to enhance immune responses against the…

Sarbecovirus Ferritin Nanoparticle Vaccines as Protein or mRNA-LNP Elicit Broad Immunogenicity

Background: The need for SARS-CoV-2 next-generation vaccines is clear. Early in the COVID-19 pandemic, we designed and characterized four categories of engineered ferritin nanoparticle immunogens based on the WA-1 sequence that recapitulate the structural and antigenic properties of prefusion SARS-CoV-2 Spike (S), S1, and RBD. A lead candidate, Spike-Ferritin nanoparticle (SpFN) adjuvanted with a liposomal-saponin…